| Literature DB >> 24744141 |
Xianwei Mo1, Yang Yang, Hao Lai, Jun Xiao, Ke He, Jiansi Chen, Yuan Lin.
Abstract
The mechanisms involved in the development of wound metastasis following laparoscopic abdominal tumor surgery remain unclear. The aim of this study was to accurately assess whether the duration of carbon dioxide pneumoperitoneum (CDP) during laparoscopic abdominal tumor surgery enhances wound metastases. We conducted a systematic review of PubMed, Cochrane Library, and Embase through December 2013 to identify animal experiments comparing wound recurrence between laparoscopic and gasless laparoscopic procedures or open procedures. The outcome of interest was the number of animals with a wound tumor. Meta-regression was used to assess whether heterogeneity was explained by study level covariates (animal model, study size, CDP pressure, duration, and evaluated time). Twenty randomized control studies involving 1,229 animals were included. Wound recurrence was not significant in the laparoscopic surgery (LP) vs. gasless laparoscopic surgery (GLP) subgroups [odds ratio (OR), 2.23; 95 % confidence interval (CI), 0.90-5.55; P = 0.08) or the LP vs. laparotomy (LA) subgroups (OR, 0.97; 95 % CI, 0.31-3.00; P = 0.08). Overall postoperative wound recurrence results were not significantly different between the study groups and controls (OR, 1.47; 95 % CI, 0.74-2.92; P = 0.28). A meta-regression analysis showed that the outcome was not correlated with the covariates (animal model: P = 0.82; evaluated time: P = 0.30; pressure of CDP: P = 0.12; duration time: P = 0.80). Current evidence suggests that CDP does not enhance wound metastases following laparoscopic abdominal tumor surgery. Additional large sample, well-designed, randomized, controlled trials are needed to further confirm whether CDP duration in laparoscopic abdominal tumor surgery significantly enhances wound recurrence.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24744141 PMCID: PMC4158183 DOI: 10.1007/s13277-014-1812-5
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283
Fig. 1Flow chart for the systematic search and study selection strategy
Characteristics of the studies included
| First author | Year of publication | Study design | Country | Animal model | Number of animal (case vs. control) | Tumor cell line | Postoperative evaluate date | Length of incisions (case vs. control) | Pressure of CDP | Duration |
|---|---|---|---|---|---|---|---|---|---|---|
| Jones | 1995 | RCT | USA | Hamsters | 50 vs. 41 (LP vs. GLP) | GW-39 human colon cancer cells | 6 weeks | A 1-cm incision + four 5-mm incisions were made in all animals | 10 mmHg | 10 min |
| Mathew | 1996 | RCT | Australia | Rats | 12 vs. 12 (LP vs. LA) | Mammary adenocarcinoma tumor cells | 1 week | A 2-mm incision vs. a 3-cm incision | 2 mmHg | 60 min |
| Mathew | 1997 | RCT | Australia | Rats | Group 1—12 vs. 12 (LP vs. GLP) Group 2—12 vs. 12 (LP vs. LA) | Viable DA mammary adenocarcinoma cells | 6 days | NA | 4 mmHg | 45 min |
| Hubens | 1996 | RCT | Belgium | Rats | 10 vs. 10 (LP vs. LA) | Colon carcinoma cell line (CC531) | 8 weeks | NA | 10 mmHg | 15 min |
| Moine | 1998 | RCT | France | Rats | Group 1—10 vs. 13 (LP vs. LA) Group 2—10 vs. 13 (LP vs. LA) | Neoplastic cells | 8 weeks | NA | 12 mmHg | 20 min |
| Wu | 1998 | RCT | USA | Hamsters | Group 1—32 vs. 31 (LP vs. GLP) Group 2—40 vs. 38 (LP vs. GLP) | GW-39 human colon cancer cell | 7 weeks | A 1-cm incision + four 5-mm incisions were made in all animals | 10 mmHg | 10 min |
| Watson | 1997 | RCT | Australia | Rats | 12 vs. 12 (LP vs. GLP) | Adenocarcinoma tumor cells | 1 weeks | NA | 2 mmHg | 60 min |
| Canis | 1998 | RCT | France | Rats | Group 1—24 vs. 23 (LP vs. LA) Group 2—24 vs. 23 (LP vs. LA) | BD IX rat ovarian adenocarcinoma cells | 2 weeks | NA | 10 mmHg 4 mmHg | 45 min |
| Lee | 1998 | RCT | USA | Mice | 32 vs. 31 (LP vs. GLP) | Murine colon 26 adenocarcinoma cell line | 10 days | Three 5-mm incisions + 1-cm incision were made in all animals | 4–6 mmHg | 20 min |
| Lee | 2000 | RCT | USA | Mice | 54 vs. 56 (LP vs. LA) | Murine colon 26 adenocarcinoma cell line | 7 days | Three 5-mm incisions + 1-cm incision were made in all animals | 4–6 mmHg | 20 min |
| Paik | 1998 | RCT | USA | Rats | 57 vs. 50 (LP vs. GLP) | DHD/K-12 rat colon carcinoma cells | 3 weeks | Two 5-mm incisions vs. a 5-cm incision | 15 mmHg | NA |
| Hopkins | 1999 | RCT | USA | Rats | Group 1—8 vs. 8 (LP vs. GLP) Group 2—8 vs. 8 (LP vs. LA) | Viable MAT B III rat mammary adenocarcinoma cells | 7 days | NA | 7–8 mmHg | 2 h |
| Hofstetter | 2000 | RCT | USA | Rats | 47 vs. 59 (LP vs. LA) | Colon cancer cells (DHD-K12) | 3 weeks | A 3-cm incision vs. a 3-cm incision | 10 mmHg | 15 min |
| Tsivian | 2000 | RCT | Israel | Mice | 20 vs. 20 (LP vs. LA) | Renal cell carcinoma cell line | 2 weeks | A 3-mm incision vs. a 2-cm incision | 5 mmHg | 15 min |
| Gutt | 1999 | RCT | Germany | Rats | Group 1—11 vs. 11 (LP vs. GLP) Group 2—11 vs. 11 (LP vs. LA) | CC 531 cells | 24 days | Three 3-mm incisions vs. three 3-mm incisions three 3 mm incisions vs. a 1 cm incision | 7 mmHg | 90 min |
| Ishida | 2000 | RCT | Japan | Rabbits | Group 1—15 vs. 15 (LP vs. GLP) Group 2—15 vs. 13 (LP vs. LA) | VX2 cancer cells | 17 days | Nine 5-mm incisions were made in all animals | 8 mmHg | 30 min |
| Tomita | 2001 | RCT | USA | Rats | 50 vs. 52 (LP vs. GLP) | WB2054Ms tumor cells | 4 weeks | A 5-mm incision vs. a 4-cm incision | 6 mmHg | 40.4 min |
| Wilkinson | 2001 | RCT | USA | Rabbits | 15 vs. 16 (LP vs. LA) | VX-2 carcinoma cell | 7–14 days | A 5-mm incision and a 3-mm incision vs. 4-cm incision | 8–10 mmHg | NA |
| Brundell | 2002 | RCT | Australia | Rats | 20 vs. 10 (LP vs. LA) | Dark Agouti mammary adenocarcinoma cells | 15 days | A 2-mm incision vs. a 2.5-cm incision | 2 mmHg | 15 min |
| Zayyan | 2003 | RCT | UK | Rats | Group 1—20 vs. 15 (LP vs. GLP) Group 2—20 vs. 15 (LP vs. GLP) | Transplantable rat colon cancer cells | 4 weeks | Two 5-mm incisions were made in all animals | 4–6 mmHg | 30–45 min |
NA not available, LP laparoscopy, GLP gasless laparoscopy, LA laparotomy, mm millimeter, cm centimeter
Quality assessment of the included studies
| Jones et al. [ | Mathew et al. [ | Mathew et al. [ | Hubens et al. [ | Le Moine et al. [ | Wu et al. [ | Watson et al. [ | Canis et al. [ | Lee et al. [ | Lee et al. [ | Paik et al. [ | Hopkins et al. [ | Hofstetter et al. [ | Tsivian et al. [ | Gutt et al. [ | Ishida et al. [ | Tomita et al. [ | Wilkinson et al. [ | Brundell et al. [ | Zayyan et al. [ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IV |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| V |
|
| – | – | – |
|
|
| – | – |
|
| – | – | – | – |
| – |
| – |
| VI | – |
| – | – | – | – | – | – | – | – | – | – |
| – | – | – | – | – | – | – |
| TS | 7 | 8 | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 7 | 6 |
| G | A | A | B | B | B | A | A | A | B | B | A | A | A | B | B | B | A | B | A | B |
√: complete data; – : not stated; √−: incomplete data. I (score of 2): peer-reviewed publication; II (score of 2): Random allocation of treatment and control; III (score of 2): animal species (inbred line, age-matched, MHC (mismatch); IV (score of 1): sample size calculation (sample size of both control and experimental groups must be clarified); V (score of 1): compliance with animal welfare regulation; and VI (score of 1): statement of potential conflict of interest (source of funds must be clarified). Study quality was stratified into four ranks according to their scores: A (a score of 7–9); B (a score of 5–6); C (a score of 3–4); D (a score of 0–2)
TS total score, G grade
Fig. 2Forest plots of number of animals with wound tumor in subgroup analysis using a random-effect model
Fig. 3Funnel plot analysis to detect publication bias; each point represents a separate study for the indicated association